[go: up one dir, main page]

WO2003008380A1 - Derives d'acide carboxylique - Google Patents

Derives d'acide carboxylique Download PDF

Info

Publication number
WO2003008380A1
WO2003008380A1 PCT/JP2002/007250 JP0207250W WO03008380A1 WO 2003008380 A1 WO2003008380 A1 WO 2003008380A1 JP 0207250 W JP0207250 W JP 0207250W WO 03008380 A1 WO03008380 A1 WO 03008380A1
Authority
WO
WIPO (PCT)
Prior art keywords
carboxylic acid
acid derivatives
compounds
derivatives
gpia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2002/007250
Other languages
English (en)
Japanese (ja)
Inventor
Masaru Takayanagi
Naoyuki Fukuchi
Masayuki Sugiki
Fumie Futaki
Shunji Takehana
Yuki Kajigaya
Yayoi Takamatsu
Munetaka Tokumasu
Kaoru Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Publication of WO2003008380A1 publication Critical patent/WO2003008380A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne les composés représentés par la formule (I) qui présentent une activité inhibitrice de l'intégrine α2β1 (inhibition de la liaison entre GPIa/IIa et collagène) ou des analogues desdits composés. L'invention concerne également un agent thérapeutique ou prophylactique pour diverses maladies qui contient n'importe lequel desdits composés et dérivés.
PCT/JP2002/007250 2001-07-18 2002-07-17 Derives d'acide carboxylique Ceased WO2003008380A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001-218507 2001-07-18
JP2001218507 2001-07-18
JP2001351077A JP2005022976A (ja) 2001-07-18 2001-11-16 カルボン酸誘導体
JP2001-351077 2001-11-16

Publications (1)

Publication Number Publication Date
WO2003008380A1 true WO2003008380A1 (fr) 2003-01-30

Family

ID=26618950

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2002/007250 Ceased WO2003008380A1 (fr) 2001-07-18 2002-07-17 Derives d'acide carboxylique

Country Status (2)

Country Link
JP (1) JP2005022976A (fr)
WO (1) WO2003008380A1 (fr)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007034035A1 (fr) * 2005-09-16 2007-03-29 Biotie Therapies Corporation Dérivés sulfonamide
JP2007536355A (ja) * 2004-05-07 2007-12-13 ラボラトワール フルニエ エス・アー Ｌｘｒ受容体モジュレーター
US7691843B2 (en) 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
US7910609B2 (en) 2005-06-07 2011-03-22 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 with modified urea moiety
CN102234313A (zh) * 2011-08-16 2011-11-09 青岛康地恩药业股份有限公司 一种匹多莫德的合成方法
WO2012038942A1 (fr) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Inhibiteurs de métalloprotéinase matricielle
US8987306B2 (en) 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
US10131658B2 (en) 2013-09-30 2018-11-20 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283545A (en) * 1976-01-01 1977-07-12 Mitsubishi Chem Ind Ltd Tri-and tetrapeptides and their derivatives
JPS62126197A (ja) * 1985-11-26 1987-06-08 Nitto Boseki Co Ltd 新規な血漿キニノゲナーゼ測定用化合物
JPH01117900A (ja) * 1987-10-30 1989-05-10 Nitto Boseki Co Ltd トリペプチド類及びこれを含有する抗プラスミン剤
JPH0242047A (ja) * 1988-05-27 1990-02-13 Pfizer Inc シクロアルキル―置換されたグルタルアミド利尿剤
JPH02275886A (ja) * 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
JPH05500954A (ja) * 1989-09-29 1993-02-25 ローヌ―プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド 抗血栓性ペプチド及び疑似ペプチド
JPH07501788A (ja) * 1991-08-09 1995-02-23 ユニロイヤル　ケミカル　カンパニー　インコーポレイテッド 除草剤としてのベンゼンスルホンアミド誘導体
JPH08505860A (ja) * 1993-01-23 1996-06-25 カセラ・アクチェンゲゼルシャフト 置換されたアミノ化合物、その製造方法及びこれを血小板凝集の阻害物質として使用する方法
WO1999006436A1 (fr) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Composes de benzyle inhibant une adhesion de leucocytes regulee par vla-4
WO1999006432A1 (fr) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Composes de dipeptides et associes inhibant une adhesion de leucocytes regulee par vla-4
WO1999043709A2 (fr) * 1998-02-27 1999-09-02 The Regents Of The University Of California Antagonistes de recepteur de la melanocortine et modulations de l'activite de recepteur de la melanocortine
WO2000043415A1 (fr) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Composes inhibant l'adhesion des leucocytaire provoquee par vla-4
WO2001054690A1 (fr) * 2000-01-28 2001-08-02 Biogen, Inc. Compositions pharmaceutiques contenant des composes d'integrine anti-beta 1 et utilisations correspondantes

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5283545A (en) * 1976-01-01 1977-07-12 Mitsubishi Chem Ind Ltd Tri-and tetrapeptides and their derivatives
JPS62126197A (ja) * 1985-11-26 1987-06-08 Nitto Boseki Co Ltd 新規な血漿キニノゲナーゼ測定用化合物
JPH01117900A (ja) * 1987-10-30 1989-05-10 Nitto Boseki Co Ltd トリペプチド類及びこれを含有する抗プラスミン剤
JPH0242047A (ja) * 1988-05-27 1990-02-13 Pfizer Inc シクロアルキル―置換されたグルタルアミド利尿剤
JPH02275886A (ja) * 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
JPH05500954A (ja) * 1989-09-29 1993-02-25 ローヌ―プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド 抗血栓性ペプチド及び疑似ペプチド
JPH07501788A (ja) * 1991-08-09 1995-02-23 ユニロイヤル　ケミカル　カンパニー　インコーポレイテッド 除草剤としてのベンゼンスルホンアミド誘導体
JPH08505860A (ja) * 1993-01-23 1996-06-25 カセラ・アクチェンゲゼルシャフト 置換されたアミノ化合物、その製造方法及びこれを血小板凝集の阻害物質として使用する方法
WO1999006436A1 (fr) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Composes de benzyle inhibant une adhesion de leucocytes regulee par vla-4
WO1999006432A1 (fr) * 1997-07-31 1999-02-11 Elan Pharmaceuticals, Inc. Composes de dipeptides et associes inhibant une adhesion de leucocytes regulee par vla-4
WO1999043709A2 (fr) * 1998-02-27 1999-09-02 The Regents Of The University Of California Antagonistes de recepteur de la melanocortine et modulations de l'activite de recepteur de la melanocortine
WO2000043415A1 (fr) * 1999-01-25 2000-07-27 Elan Pharmaceuticals, Inc. Composes inhibant l'adhesion des leucocytaire provoquee par vla-4
WO2001054690A1 (fr) * 2000-01-28 2001-08-02 Biogen, Inc. Compositions pharmaceutiques contenant des composes d'integrine anti-beta 1 et utilisations correspondantes

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GAERTNER H. ET AL.: "Peptide synthesis catalyzed by modified .alpha.-chymotrypsin in low-water organic media", J. ORG. CHEM., vol. 56, no. 9, 1991, pages 3149 - 3153, XP001009792 *
HAGIWARA DAIJIRO ET AL.: "Studies on neurokinin antagonists. 3. Design and structure-activity relationships of new branched tripeptides N.alpha.-(substituted L-aspartyl, L-ornithyl, or L-lysyl)-N-methyl-N-(phenylmethyl)-L-phenylalaninamides as substance P antagonists", J. MED. CHEM., vol. 36, no. 16, 1993, pages 2266 - 2278, XP002006315 *
HELLIO FLORENCE, GUEGUEN PAUL, MORGAT JEAN LOUIS: "Peptide enzymic microsynthesis, using carboxypeptidase Y as the catalyst: application to stepwise synthesis of Leu-enkephalin", BIOCHIMIE, vol. 70, no. 6, 1988, pages 791 - 802, XP002956674 *
OKA TATSUSHI, MORIHARA KAZUYUKI: "Trypsin as a catalyst for peptide synthesis", J. BIOCHEM., vol. 82, no. 4, 1977, TOKYO, pages 1055 - 1062, XP001011246 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691843B2 (en) 2002-07-11 2010-04-06 Pfizer Inc. N-hydroxyamide derivatives possessing antibacterial activity
JP2007536355A (ja) * 2004-05-07 2007-12-13 ラボラトワール フルニエ エス・アー Ｌｘｒ受容体モジュレーター
JP4892475B2 (ja) * 2004-05-07 2012-03-07 ラボラトワール フルニエ エス・アー Ｌｘｒ受容体モジュレーター
US7910609B2 (en) 2005-06-07 2011-03-22 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 with modified urea moiety
US8258159B2 (en) 2005-06-07 2012-09-04 The Trustees Of The University Of Pennsylvania Inhibitors of the α2β1/GPIa-IIa integrin
US8987306B2 (en) 2005-06-07 2015-03-24 The Trustees Of The University Of Pennsylvania Inhibitors of integrin alpha2beta1 based on prolyl diaminopropionic acid scaffold
WO2007034035A1 (fr) * 2005-09-16 2007-03-29 Biotie Therapies Corporation Dérivés sulfonamide
WO2012038942A1 (fr) 2010-09-24 2012-03-29 Ranbaxy Laboratories Limited Inhibiteurs de métalloprotéinase matricielle
CN102234313A (zh) * 2011-08-16 2011-11-09 青岛康地恩药业股份有限公司 一种匹多莫德的合成方法
US10131658B2 (en) 2013-09-30 2018-11-20 The Regents Of The University Of California Anti-alphavbeta1 integrin compounds and methods
US10214522B2 (en) 2015-03-10 2019-02-26 The Regents Of The University Of California Anti-alphavbeta1 integrin inhibitors and methods of use
US11116760B2 (en) 2018-10-30 2021-09-14 Gilead Sciences, Inc. Quinoline derivatives
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
US11179383B2 (en) 2018-10-30 2021-11-23 Gilead Sciences, Inc. Compounds for inhibition of α4β7 integrin
US11224600B2 (en) 2018-10-30 2022-01-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US12053462B2 (en) 2018-10-30 2024-08-06 Gilead Sciences, Inc. Quinoline derivatives
US11578069B2 (en) 2019-08-14 2023-02-14 Gilead Sciences, Inc. Compounds for inhibition of α4 β7 integrin
US11952365B2 (en) 2020-06-10 2024-04-09 Aligos Therapeutics, Inc. Anti-viral compounds
US11851422B2 (en) 2021-07-09 2023-12-26 Aligos Therapeutics, Inc. Anti-viral compounds
US12252481B2 (en) 2021-07-09 2025-03-18 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds

Also Published As

Publication number Publication date
JP2005022976A (ja) 2005-01-27

Similar Documents

Publication Publication Date Title
WO2003008380A1 (fr) Derives d'acide carboxylique
WO2002098869A3 (fr) Composes de cycloalkyl uree condense avec un 1,4-disubstitue benzo
WO2005000332A3 (fr) Agent therapeutique contre le sarcome des tissus mous
EP1889842A4 (fr) Composé hétérocyclique
MXPA04004674A (es) Ligados de los receptors de los canabinodies.
WO2003048081A3 (fr) Glycinamides en tant qu'inhibiteurs du facteur xa
NO20032233L (no) Synergistiske foreninger som innbefatter en renininhibitor for kardiovaskulaere sykdommer
GB0111523D0 (en) Chemical compounds
AU2002363746A1 (en) Inventory early warning agent with correction by error correlation calculation
WO2003006425A3 (fr) Nouveaux composes convenant comme anti-inflammatoires, immuno-modulateurs et anti-proliferants
AU2003298861A1 (en) Anti-backup mechanism for repeating multi-clip applier
WO2003000220A3 (fr) Utilisation de 1,2-decandiol pour lutter contre des germes induisant des odeurs corporelles
CL2008003324A1 (es) Formulacion farmaceutica liquida de liberacion inmediata que comprende una sal de adicion de acido de un compuesto derivado de azetidina sustituido y un diluyente o portador farmaceuticamente aceptable, util para el tratamiento o prevencion de trombosis.
WO2004014893A3 (fr) Quinolones anti-microbiens, leurs compositions et utilisation
WO2003082205A3 (fr) Composes et procedes
WO2002076935A8 (fr) Nouveau derive de l'acide lipoique et son utilisation
WO2002080899A1 (fr) Agent de traitement de maladie digestive
WO2003047520A3 (fr) Inhibiteurs de facteur xa a aminomethyle substitue
WO2002092122A3 (fr) Utilisation d'osteopontine dans le traitement et/ou la prevention de maladies neurologiques
WO2002034201A3 (fr) Utilisation d'inhibiteurs de l'apoptose des pericytes pour le traitement et/ou la prevention de la retinopathie diabetique
CA2468039A1 (fr) Nouveau peptide exercant un effet inhibiteur d'angiotensine convertase
WO2002092072A3 (fr) Medicaments contre la maladie d'alzheimer
WO2003078574A3 (fr) Nouveaux marqueurs et cibles metaboliques
WO2003024933A1 (fr) Derive d'acide 2-phenyle-3-heteroarylpropionique ou son sel et medicaments le contenant
WO2003035650A1 (fr) Inhibiteur d'entree

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP